Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism ofERCC1: a meta-analysis
- 5 February 2014
- journal article
- research article
- Published by Taylor & Francis in Biomarkers
- Vol. 19 (2) , 128-134
Abstract
Background: In the present study, we performed this meta-analysis to estimate the association between excision repair cross-complementation group 1 (ERCC1) gene polymorphism and clinical resistance to platinum-based chemotherapy in the patients with epithelial ovarian cancer (EOC). Methods: A total of 10 studies consist of 1479 EOC patients relating ERCC1 rs11615C/T and rs3212986C/A polymorphisms to the response of platinum-based chemotherapy were included in this meta-analysis. Results: The analysis showed that the AA genotype of the rs3212986C/A polymorphism in ERCC1 was associated with progression-free survival of EOC patients (HR = 1.39, 95% CI = 1.12–1.73) and that the CA or AA genotypes could influence overall survival (HR = 1.28, 95% CI = 1.05–1.56; and HR = 1.55, 95% CI = 1.17∼2.05, respectively). Conclusions: The ERCC1 rs3212986C/A polymorphism may be a useful prognostic marker in platinum-based treatment of EOC.Keywords
This publication has 31 references indexed in Scilit:
- Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinumGynecologic Oncology, 2012
- Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapyVirchows Archiv, 2011
- Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patientsThe Pharmacogenomics Journal, 2009
- Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: A Korean population-based studyGynecologic Oncology, 2009
- Molecular determinants of efficacy for 5‐FU‐based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy‐related genesInternational Journal of Cancer, 2008
- Excision Repair Cross Complementing-1 and Topoisomerase IIα Gene Expression in Small-Cell Lung Cancer Patients Treated with Platinum and Etoposide: A Retrospective StudyJournal of Thoracic Oncology, 2008
- Current status of excision repair cross complementing-group 1 (ERCC1) in cancerCancer Treatment Reviews, 2007
- Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancerExperimental & Molecular Medicine, 2006
- Cancer of the OvaryNew England Journal of Medicine, 2004
- Carcinoma of the ovaryInternational Journal of Gynecology & Obstetrics, 2003